IVI-RA Value Model

A Flexible Modeling Platform for Rheumatoid Arthritis

Rheumatoid Arthritis (RA) is the most common autoimmune inflammatory arthritis in adults and often negatively impacts patients’ quality of life and ability to perform daily activities.

To help decision-makers identify high-value treatments for patients with RA, the IVI-RA model simulates the lifetime costs and benefits of different strategies for treating patients with moderate to severe rheumatoid arthritis.

How Does the IVI-RA Model Work?

The IVI-RA model is an open-source simulation model that decision-makers can use to assess the value of different sequences of disease-modifying anti-rheumatic drugs (DMARDs). Specifically, the IVI-RA model provides information on expected health benefits, risks and costs for patients with moderate to severe RA.

Incorporating the Patient Perspective

See how we worked with patients and other stakeholders to build Version 1 of the IVI-RA Value Model.

Application in the Real World

Learn about the mechanics of the IVI-RA model and see specific examples of how it can be used.

Review IVI-RA Model Detailed Methodology

Click here to learn more about the technical details on how the IVI-RA model is constructed.

Get Started with the IVI-RA Value Model

The IVI-RA model features easy-to-use web-based interfaces designed to help healthcare decision-makers evaluate treatment strategies for rheumatoid arthritis.

Two versions of the IVI-RA interface are available.

The Basic interface is designed to provide a streamlined experience for general audience users with limited expertise.
The Advanced interface is designed for users with clinical or technical expertise and provides complete control over all modeling.

RESOURCES

PUBLIC COMMENTS

· December 2023
· 2022

MODEL RESOURCES

· iviNSCLC R Package
· Source Code

The IVI-RA model, part of the Open-Source Value Project (OSVP), was created, developed, and is owned by Precision Health Economics LLC (now PRECISIONheor) and is licensed to IVI Foundation, Inc. for its use in connection with redefining how value of pharmaceutical treatment is assessed. In keeping with IVI’s philosophy, this includes sharing and distribution of source code, data and parameter inputs, and any additional materials and technical documentation supporting open use, distribution, and adaptation of the model with attribution to the model developers.

In addition, any work performed by IVI based on the IVI-RA model is conducted as part of the OSVP and is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license visit: https://creativecommons.org/licenses/by/4.0/.